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This paper discusses the use of cancer incidence data in identification of cancer causation.
Selective descriptive and analytical epidemiological studies were reviewed. These examples
were taken primarily from Denmark, where the possibilities for epidemiological research are good
due to the existence of many exposure and disease registers. Descriptive studies are still needed
for a better understanding of cancer. Analytical studies of individual risk factors today often show
relative risks of only 1.5 to 2, and these are difficult to translate into preventive recommendations.
Epidemiology still remains the best available tool for identification of risk factors. Environ
Health Perspect 104(Suppl 3):639-641 (1996)
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Background
Epidemiology has favorable conditions in
countries with stable populations and good
registers. Denmark benefits from a long
tradition in this field. Deaths, births, and
marriages have been systematically recorded
for more than 300 years. All causes of
death and all new cancer cases have been
registered, beginning in 1943.
Important observations from the first
years of cancer registration in Denmark
were the hook on the incidence curve for
breast cancer amongwomen around the age
ofmenopause (1) and the the 4-fold differ-
ence in incidence ofcervical cancer between
poor inner-city and affluent neighborhoods
ofCopenhagen (2).
In the late 1960s, cancer incidence
data became available from populations
throughout the world (3,4). These data
showed wide variations in the incidence of
different cancer sites. For example, the rate
of stomach cancer for men in Japan was
close to five times the rate in the United
States, and the rate ofcolon cancer for men
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in the United States was close to seven
times the rate in Japan. Based on these
data, a theoretical overall cancer incidence
rate was calculated by adding the lowest
observed rates for each cancer site. The
observed overall cancer incidence rates for
men throughout the world in the 1960s
were between 3 and 15 times this theoreti-
cal rate (5). This led Higginson and Muir
to their famous statement that "the signi-
ficance of these observations, indicating
that 80 to 90% of cancers are due to
external factors and are thus theoretically
preventable, is obvious" (5).
Descriptive Epidemiology
Today, simple descriptive studies are still
needed to solve the mystery ofmany cancer
diseases. Such studies would not be possi-
ble without the routinely collected data on
cancer mortality and cancer incidence.
As pointed out recently by Beral et al.
(6), the worldwide decline in cervical
cancer incidence and mortality predates the
introduction of screening; even though
infection with certain types of human
papilloma virus (HPV) is the main cause of
cervical cancer, "it seems unlikely that a
decline in the prevalence ofHPV infection
over time is the main reason for the overall
decline in cervical cancer" (6). These
declining trends in cervical cancer can be
illustrated based on mortality data alone.
Testicular cancer is a disease that is
increasing, and in-depth case-control
studies have failed to identify major risk
factors apart from cryptorchidism, which
can only explain 10% of the cases. The
major improvements in the treatment of
testis cancer patients imply that mortality
data are oflittle value in studies ofdisease
etiology. The long-time series on testis
cancer incidence from the countries around
the Baltic Sea have proved valuable in
showing a highly puzzling east-west
gradient; there is a low rate in Finland,
Poland, and the Baltic countries; an inter-
mediate rate in Sweden; a higher rate in
Norway, Saarland, and the former German
Democratic Republic; and a world record
in Denmark (7).
Comparison ofmortality and incidence
trends can also reveal patterns that are not
so easily understood. From 1960 onward
the breast cancer incidence in Denmark has
almost doubled, whereas the breast cancer
mortality has remained relatively stable.
These diverging trends have developed
prior to the introduction ofmammographic
screening, and although improvements in
breast cancer therapy have taken place,
they are unlikely to explain the difference
(8). It is an advantage here to have data
going back to the 1940s. A recent analysis
based on the U.S. SEER (Surveillance,
Epidemiology, and End Results data covers
the periods 1975 to 1979 to 1987 to 1991;
diverging trends between the incidence and
the mortality in this period in the United
States are more likely to be explained by
early detection (9).
The importance of classic studies of
social class distributions should also be
stressed. Recent studies have shown that
the social class gradient in lung cancer is
modified but remains when controls for
differences in smoking habits are used (10).
Analytical Epidemiology
Analytical epidemiological studies have
been decisive for the identification of all
the known carcinogens. This is clearly
illustrated with the example ofasbestos and
lung cancer. The first case reports on this
topic were published in the 1930s (11-13),
but uncertainty about a causal association
remained until results were available from
analytical epidemiological studies in the
1960s (14-16).
The conditions for analytical epidemio-
logical studies are particularly good in the
Nordic countries where personal identi-
fication numbers are used in all public and
in many private registers. An example from
Denmark of a study concerning environ-
mental risk factors is a nationwide cohort
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study linking records from the 1970 cen-
sus, the Central Population Register, the
National Death Register, and the National
Cancer Register. Based on this linked regis-
ter, for example, an excess risk ofleukemia
has been observed among persons in occu-
pations/industries probably exposed to
magnetic fields continuously higher than
the background level. Of 1.3 million eco-
nomically active men in 1970, 18,000 men
were classified as exposed according to
codes assigned by two independent experts.
During a 17-year follow-up period, 39
incident leukemia cases were diagnosed in
this group in which 23.80 cases were
expected (standardized incidence ratio
[SIR], 1.64; 95%CI, 1.20-2.24) (17).
The combination of registers also
makes it possible to collect cancer inci-
dence data for workers from many small
and closed workplaces. An example is a
study from the reinforced plastics industry
in which boats and similar products were
made in workshops that often existed for
only a few years and where less than 10
persons were employed at the time. The
study included 54,000 men identified from
a combination ofdata from the Institute of
Occupational Health air measurements
records, the Work Inspection Service, the
Danish Plastics Association, the Unskilled
and Semiskilled Workers Union, the Local
Environment Authorities, the Industry
Register in the Central Bureau ofStatistics,
telephone books, the National Custom and
Tax Administration, the Supplementary
Pension Fund, the Central Population
Register, the National Death Register, and
the National Cancer Register. Air monitor-
ing data showed the average exposure level
to styrene to have been 180 ppm in 1964
to 1970, 88 ppm in 1971 to 1975, and 43
ppm in 1976 to 1988. Men first employed
in 1964 to 1970 had an excess risk ofleu-
kemia based on 30 incident cases (expected
number [exp] 19.53; SIR, 1.54; 95%CI,
1.04-2.19), whereas no excess risk was
observed among men first employed after
1970 (observed [obs], 12; exp, 14.86; SIR,
0.81; 95%CI, 0.42-1.41) (18).
Limits of Epidemiology
The examples above clearly illustrate that
good registers by themselves do not enable
us to overcome the limits ofmodern epi-
demiology. After combining all these data
sources, the studies often end up with rela-
tive risks of about 1.5 to 2. In a recent
interview in Science (19), Richard Doll,
Dimitrios Trichopoulos, Marcia Angell,
and Robert Temple all said that relative
risks of 3 to 4 were required for them to
trust new findings. This statement has later
been modified by Trichopoulos (20). But
the general problem remains: with relative
risks of 1.5, epidemiologists are unable to
give the public a clear answer-and they
might even scare people unnecessarily.
Relative risks of 3 to 4 are rare in
cancer epidemiology today. At the same
time, epidemiological research is poten-
tially hampered by the concern about data
confidentiality (21), and on the experi-
mental side of cancer research, major
breakthroughs in the understanding ofthe
role ofmutations in genes for tumor devel-
opment are reported (22-24). The priority
questions are therefore pertinent in cancer
research today.
What to Do with the 1.5
Relative Risks?
Many ofthe 1.5 relative risk studies address
important environmental and occupational
pollutants such as formaldehyde, trichloro-
ethylene, diesel exhaust, etc. To assess the
safety ofsuch exposures remains an impor-
tant task. Epidemiology has limitations,
but so have experimental studies. In classi-
fication of chemicals, the arguments
inevitably arise that epidemiological data
cannot be trusted because not all potential
confounders have been controlled for,
and animal data cannot be trusted due
to potential interspecies differences. But
conclusions are needed in practical life.
A framework for decisions on carcino-
genicity has been established in the mono-
graph program ofthe International Agency
for Research on Cancer (IARC). Today,
systematic IARC evaluations ofthe consis-
tency in the overall epidemiological and
experimental evidence provide the best
method of preventing the public from
being frightened by press releases from
single or conflicting studies. In a systematic
evaluation, one study forms only a part
of the basic work needed to determine
whether a given exposure can be consid-
ered carcinogenic, probably carcinogenic,
orpossibly carcinogenic.
It is, however, a real problem when the
evaluation of the epidemiology cannot
result in a clear-cut answer. Epidemiology
studies on formaldehyde, for example, were
summarized as showing "limited evidence
in humans," despite the fact that 14 cohort
studies and 23 case-control studies were
available (25). For the moment, one must
accept that that is the way things are.
Evaluations ofepidemiological and exper-
imental data translate into classification and
labeling (26), and further into regulations
for marketing, workplace exposure, drink-
ing water limits, etc. Sander Greenland has
recently been quoted as saying that
There is nothing sinful about going out
and getting evidence, like asking people
how much do you drink and checking
breast cancer records.... The sin comes in
believing a causal hypothesis is true
because your study came up with a posi-
tive result, or believing the opposite
because your studywas negative (19).
Making interpretations and evaluations,
even in the best possible way, is clearly
"sinful" business, but there is no point in
collecting data without using them.
The deadlock ofobservational epidemi-
ology will probably only be overcome
when the studies can in some way be
supplemented with molecular techniques.
At present, there are many limitations for
the use of biomarkers in exposure assess-
ment in epidemiology (27), and the results
from traditional epidemiology are neces-
sary to guide the use. As pointed out by
Bosch et al. (28) concerning the studies of
HPV and cervical cancer, "the historical
evidence based on questionnaires and
appropriate study designs was extensive
and had established the likely role of a
sexually transmitted agent."
The IARC evaluations have tradition-
ally covered chemicals but have recently
been extended to include hepatitis viruses,
HPV, and other infections like schistosomi-
asis. Today, there is clearly a need to extend
the program to include evaluations ofcom-
mon medical procedures such as vasectomy
(29-30) and induced abortion (31).
Conclusion - Optimizing
Data Generation
The availability of cancer incidence data
from populations throughout the world
was invaluable for the understanding of
cancer as a primarily preventable disease.
Descriptive studies are still needed for a
better understanding of cancer. Analytical
studies ofindividual risk factors often show
relative risks ofonly 1.5 to 2. These mod-
erately elevated relative risks are difficult
to translate into preventive recommenda-
tions; however, epidemiology remains
the best available tool for identification of
risk factors.
Furthermore, almost one in three per-
sons in developed countries today will
develop cancer. The care and treatment of
cancer patients are therefore major eco-
nomic burdens. In Denmark, with a popu-
lation of 5.1 million, 15,000 new cancer
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patients start on curable treatment every
year, and 8,000 new patients are referred
directly to palliative treatment and pain
relief (32). Besides the need for cancer
incidence data for identification ofcancer
causes, there is also a demand for cancer
incidence data for health-care planning.
The availability ofmany registers does
not only affect the possibilities for research
but also the possibilities for data generation.
In Denmark, a plan has recently been pub-
lished by the Ministry ofHealth for genera-
tion of cancer incidence data primarily
from computerized hospital records (33).
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